Interview with the Innovators
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options.
Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice.
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice.
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility.
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy.
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year and the importance of an accurate diagnosis of tumor type in selecting the proper site-specific therapies.
The interview featured in this article was conducted with Linda Bosserman, MD, FACP, at the 2014 conference of the Association for Value-Based Cancer Care. Q: What are the main value-based concerns for oncologists in the United States? Linda Bosserman, MD, [ Read More ]